At a Glance
| Ibogaine | 1P-ETH-LAD | |
|---|---|---|
| Class | Psychedelic | Psychedelic |
| Common Dose (oral) | 15–22 mg/kg of body weight | 60–100 µg |
| Total Duration | 18.5–39 hrs | 2.5–5.5 hrs |
| Routes | oral | oral |
| Effects | 71 documented | 52 documented |
Ibogaine, a Psychedelic, and 1P-ETH-LAD, a Psychedelic, are frequently compared by users looking to understand their relative effects, dosage profiles, and safety considerations. Both are classified as Psychedelics, meaning they share a common pharmacological foundation. They share 35 documented effects in common, with 36 effects unique to Ibogaine and 17 unique to 1P-ETH-LAD. This side-by-side comparison covers dosage, duration, subjective effects, and safety to help you make informed decisions.
| Ibogaine | 1P-ETH-LAD | |
|---|---|---|
| Class | Psychedelic | Psychedelic |
| Common Dose (oral) | 15–22 mg/kg of body weight | 60–100 µg |
| Total Duration | 18.5–39 hrs | 2.5–5.5 hrs |
| Routes | oral | oral |
| Effects | 71 documented | 52 documented |
| Interaction |
| Low Risk & Synergy |
| Level | Ibogaine | 1P-ETH-LAD |
|---|---|---|
| Threshold | — mg/kg of body weight | 25 µg |
| Light | — mg/kg of body weight | 30–60 µg |
| Common | 15–22 mg/kg of body weight | 60–100 µg |
| Strong | — mg/kg of body weight | 100–200 µg |
| Heavy | — mg/kg of body weight | 200 µg |
Ibogaine
1P-ETH-LAD
Cross-tolerance exists; effects compound
No dangerous interactions recorded.
No dangerous interactions recorded.